← Leaderboards
D K Turgeon
University Of Michigan At Ann Arbor
$36,038
Attributed
$36,038
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.9K · FY2005–06$20K$15K$10K$5K$0
'05
'06
Funding mix
By agency
NIH$36,038 · 3
By mechanism
M01$36,038 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Jeffrey S Chamberlain$54,800,495
- Imad Shureiqi$13,361,753
- Yatrik M Shah$14,576,569
- Eric R. Fearon$27,558,344
- Richard A. Miller$53,224,142
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyColon NeoplasmsBiopsyNonsteroidal Antiinflammatory AgentBiomarkerCancer PreventionAspirinAdenomatous PolypsProstaglandinsColon PolypCytochrome P450DifluoromethylornithineFamily GeneticsGene ExpressionGenetic DisorderGenetic RegulationPatient Oriented ResearchPolyamines
Grant awards (6)
DFMO & SULINDAC TO DECREASE RATE OF RECURRENCE OF ADENOMATOUS POLYPS IN COLON$19,928
M01 · FY2006 · RR · contact PI
DFMO &SULINDAC TO DECREASE RATE OF RECURRENCE OF ADENOMATOUS POLYPS IN COLON$11,837
M01 · FY2005 · RR
DFMO &Sulindac to Decrease Rate of Recurrence of Adenomatous Polyps in Colon$4,067
M01 · FY2004 · RR
Effect of NSAIDS upon colonic surrogate endpoint biomarkers$0
M01 · FY2002 · RR
FAMILY STUDY OF INHERITENCE OF P450IIIA4 GENE DEFECT$206
M01 · FY2000 · RR
Effect of NSAIDS upon colonic surrogate endpoint biomarkers$0
M01 · FY2000 · RR